DoW Joint Warfighter Medical, Military Medical Research and Development Award
This grant funds continued military medical research, clinical studies, and technology development for projects previously supported by DoD/DoW, aiming to meet high-priority needs for service members in FY26.
Funder: Dept. of the Army -- USAMRAA
Due Dates: August 18, 2026: Preapplication/Preproposal | November 16, 2026: Full application/proposal | November 23, 2026: End of application/proposal verification period
Funding Amounts: ~$8.8M total; up to $1.4M per MMRDA award, up to $3.0M per MMRDA-CRCTO award; max 3 years/project; ~4 awards expected
Summary: Supports continuation of previously DoD/DoW-funded military medical R&D efforts to accelerate high-priority medical solutions for Service Members and the Military Health System.
Key Information: Applicants must have prior DoD/DoW core or Congressional Special Interest funding for the proposed research area.
Description
This opportunity funds the logical continuation of previous Department of War (DoW) or Department of Defense (DoD)-funded research and development efforts relevant to the FY26 Joint Warfighter Medical Research Program (JWMRP). The goal is to augment and accelerate high-priority medical requirements to address the needs of Service Members and other Military Health System beneficiaries. The award supports projects spanning late-stage preclinical studies, technology development, technology demonstration, translational, and clinical research.
Projects must address at least one of the FY26 JWMRP focus areas and demonstrate a clear path to military relevance and impact. Clinical research and clinical trial options (MMRDA-CRCTO) are available specifically for studies involving human subjects, biological samples, or human datasets.
Distinctive features:
- Only applicants with prior DoD/DoW core or Congressional Special Interest funding (including SBIR/STTR) for the research area are eligible.
- Not for new project concepts or basic research—must be a logical continuation.
- Both applied research and advanced development are supported, but not procurement.
